Clinical Trial Agreements: Key Clauses and Negotiation

A clinical trial agreement (CTA) is a legally binding contract between a sponsor (typically a pharmaceutical or medical device company) and an institution, usually a university or academic medical centre, to conduct a clinical trial. CTAs govern the terms under which an investigator at the institution will enrol patients, administer a study drug or device, and collect data according to the sponsor’s protocol.

CTAs are among the most complex research agreements that contract offices handle. They sit at the intersection of regulatory compliance, patient safety, detailed budgeting, IP considerations, and significant liability exposure. A single agreement may involve the principal investigator, the research office, the IRB or ethics committee, the pharmacy, the finance team, and outside counsel, all before a single patient is enrolled.

This guide covers the key provisions in a CTA, common negotiation challenges, and practical approaches to managing CTA workflows at scale.

How CTAs Differ from Other Research Agreements

If your office manages multiple types of research agreements, it helps to understand where a CTA fits in the landscape.

CTA vs Sponsored Research Agreement (SRA). A CTA is essentially a specialised form of SRA designed for clinical research. The core structure is similar, as a sponsor funds research performed at the institution, but a CTA adds layers of regulatory obligation (GCP compliance, IRB approval, adverse event reporting), patient safety provisions, and subject injury clauses that a standard SRA does not require.

CTA vs Research Collaboration Agreement (RCA). If the institution is genuinely co-developing the study protocol alongside the sponsor, contributing to study design and sharing intellectual leadership, an RCA may be more appropriate than a CTA. In practice, most industry-sponsored clinical trials are sponsor-initiated, meaning the sponsor owns the protocol and the institution executes it. That dynamic calls for a CTA.

Investigator-Initiated Trials (IITs). When the institution’s own researcher designs the study and the company supplies the investigational product, the dynamic reverses. The institution effectively acts as the sponsor. IITs require a different agreement structure, often a drug supply agreement combined with an investigator grant, rather than a standard CTA.

Key CTA Clauses

Every CTA negotiation centres on a set of core provisions. Here are the clauses that matter most and where negotiations typically concentrate.

Protocol and Scope

The clinical trial protocol is the foundation of the agreement. It defines the study objectives, patient population, treatment regimen, endpoints, and data collection requirements. The protocol is typically attached as a schedule to the CTA.

Changes to the protocol require formal amendments to the agreement. This sounds straightforward, but in practice, protocol amendments are frequent in multi-year trials. The CTA should specify the process for amendments, including whether changes to the protocol automatically flow through to the agreement or require separate legal review.

Budget and Payment Terms

The clinical trial budget is often the most time-consuming element to negotiate, and many institutions handle it as a separate negotiation track from the legal terms. This is usually the right approach. The budget involves finance staff, the PI, and sometimes the pharmacy, while the legal terms involve the research office and counsel.

Key budget items to address include:

• Per-patient payments tied to protocol procedures and visits.
• Screen failure costs for patients who consent but do not qualify.
• Start-up fees covering IRB review, site initiation, and regulatory submissions.
• Close-out costs for data reconciliation, archiving, and final reporting.
• Indirect costs and overhead, where institutional rates vary and sponsors often push back.

The payment schedule should specify when invoices can be submitted, how long the sponsor has to pay (net 30 is standard, but net 60 is common in practice), and what happens to payments if the trial terminates early.

IP and Inventions

Who owns inventions that arise from the trial? The sponsor, who designed the protocol and owns the investigational product, will typically want ownership of all trial-related IP. Most institutions will accept this for inventions directly related to the study drug or device, but need to protect researcher contributions that extend beyond the sponsor’s compound.

For example, if an investigator develops a novel diagnostic method during the course of a trial, that invention may have value far beyond the sponsor’s product. The CTA should address these “incidental inventions” separately, rather than sweeping them into a blanket assignment to the sponsor.

For a detailed look at how IP clauses work in research agreements, see our guide on background IP vs foreground IP.

Publication Rights

The ability to publish trial results is a fundamental principle for academic institutions. Sponsors have a legitimate interest in reviewing publications before submission to check for confidential information, to file patent applications if needed, and to ensure accuracy. However, that review right should not become a veto.

Standard practice is a 60 to 90 day review period. Multi-centre trials add an additional layer: the sponsor may require coordination of publications across sites, and some sponsors insist that multi-centre results be published before individual site data. The CTA should specify whether the investigator can publish individual site results and under what conditions.

Watch for language that allows the sponsor to delay publication indefinitely “for patent prosecution purposes.” Most institutions will accept a single, time-limited extension, not an open-ended right to suppress results.

Indemnification and Insurance

This is one of the most critical clauses in any CTA. The standard position is:

• Sponsor indemnifies the institution and its investigators for claims arising from the study drug or device, the protocol design, or information provided by the sponsor.
• Institution indemnifies the sponsor for claims arising from the institution’s own negligence or deviation from the protocol.

The negotiation challenge is usually around scope and carve-outs. Sponsors may try to exclude indemnification for claims arising from “failure to follow the protocol,” which could be interpreted broadly enough to cover honest protocol deviations. Institutions typically insist that indemnification only excludes gross negligence or wilful misconduct.

Insurance requirements should be specified: minimum coverage amounts, whether the sponsor must maintain clinical trial insurance, and whether the institution needs to add the sponsor as an additional insured.

Regulatory Compliance

CTAs must address compliance with Good Clinical Practice (GCP) guidelines as established by the International Council for Harmonisation (ICH), along with local regulatory requirements. In Singapore, the Health Sciences Authority (HSA) governs clinical trial conduct under the Health Products Act and associated regulations. Other ASEAN member states have their own regulatory authorities (Malaysia’s NPRA, Thailand’s FDA, Indonesia’s BPOM, the Philippines’ FDA) with varying levels of harmonisation under the ASEAN Joint Assessment Coordinating Group.

The CTA should require IRB or ethics committee approval before enrolment begins, and should address who is responsible for regulatory submissions, adverse event reporting timelines, and compliance with data integrity standards.

Confidentiality

Confidentiality in a CTA extends well beyond a standard NDA. It covers patient data (subject to health data protection regulations), study results before publication, the sponsor’s proprietary compound information, and the institution’s internal processes. The confidentiality clause should address the intersection with publication rights, ensuring that the obligation to keep results confidential does not override the right to publish after the review period.

Subject Injury Provisions

Who pays for the treatment of injuries that arise from the study? For most institutions, this is non-negotiable: the sponsor must cover the costs of treating study-related injuries, at minimum for injuries caused by the investigational product or protocol procedures.

Sponsors may try to limit this to injuries “directly caused” by the study drug, excluding injuries from standard-of-care procedures performed as part of the protocol. Institutions typically push back, arguing that all protocol-mandated procedures are part of the trial and the sponsor should bear the associated risk.

This clause is particularly important in jurisdictions without a universal healthcare system, where treatment costs can be substantial.

Termination

Early termination provisions should cover several scenarios: termination for safety concerns, termination for regulatory reasons, termination for convenience by either party, and termination for cause (such as material breach or loss of IRB approval).

The critical detail is the wind-down period. When a trial terminates, patients may be mid-treatment. The CTA must specify how enrolled patients are transitioned out of the study, who pays for ongoing care during the wind-down, and how long the institution must retain study records after termination.

Data Ownership and Access

The sponsor typically owns the clinical trial data, including the case report forms and the final study database. However, the institution needs access to the data for safety monitoring, regulatory compliance, and publication purposes.

The CTA should guarantee the investigator access to data from their own site, at minimum, and should address whether the institution retains copies of site-level data after the trial concludes.

Common CTA Negotiation Issues

Certain issues surface in nearly every CTA negotiation, regardless of the sponsor or the therapeutic area.

Indemnification scope and caps. Global pharmaceutical sponsors often send templates with indemnification language drafted for large Western jurisdictions, which does not translate well to Singapore or broader ASEAN. Statutory limitations on public institution liability in Singapore add another layer. Aligning indemnification language with your institution’s actual risk exposure and legal capacity is a recurring negotiation.

Publication restrictions beyond the review period. Some sponsors attempt to insert language that effectively gives them ongoing control over publications, not just a time-limited review right. This is a red line for most universities.

Budget inadequacy. Sponsors often provide a budget template that reflects their internal cost assumptions, not the institution’s actual costs. Screen failure rates, overhead calculations, and close-out costs are common points of disagreement. Negotiate the budget on a true-cost basis, not on the sponsor’s template.

IP ownership for investigator contributions. When the CTA includes a blanket IP assignment to the sponsor, it can inadvertently capture inventions that have nothing to do with the sponsor’s compound. Carve out non-trial-related inventions explicitly.

Governing law in multi-country trials. A global trial with sites in ten countries cannot practically be governed by ten different legal systems. Sponsors typically push for their home jurisdiction. Institutions should negotiate for a governing law that is practical and enforceable in their own jurisdiction. Singapore-based institutions often propose Singapore law and arbitration through SIAC, which is increasingly accepted in multi-country ASEAN trials.

Timeline pressure. Sponsors under competitive and regulatory pressure want to activate sites and begin enrolment as quickly as possible. This urgency can push institutions to accept unfavourable terms. Having standardised positions ready before the negotiation begins is the best defence against timeline pressure.

Master Clinical Trial Agreements and the ACTA Framework

If your institution regularly conducts trials with the same sponsor, negotiating a full CTA for each study is inefficient.

Master Clinical Trial Agreements are umbrella contracts that establish the standard terms (indemnification, confidentiality, publication rights, IP, governing law) between the institution and a sponsor. Individual studies are then added through shorter study-specific schedules that reference the master agreement. This approach significantly reduces negotiation time for subsequent trials and provides consistency across studies.

The ACTA (Accelerated Clinical Trial Agreement) is an industry initiative, developed initially in the UK through collaboration between the BioIndustry Association and academic institutions, to standardise CTA terms. The ACTA template provides pre-agreed positions on the most contentious clauses, including indemnification and IP, allowing institutions to adopt it as a starting point rather than negotiating from scratch.

When to use a master agreement vs a standalone CTA. If you expect to run multiple trials with a sponsor over several years, invest the time upfront to negotiate a master agreement. The first negotiation will take longer, but every subsequent study activates faster. For a one-off trial with a sponsor you may not work with again, a standalone CTA is more practical.

Managing CTA Workflows

The legal negotiation is only one part of the CTA process. Managing the internal workflow, from initial sponsor contact through to site activation, is where many institutions lose weeks or months.

Multi-Stakeholder Review

A typical CTA requires input from legal, finance, the PI, the IRB or ethics committee, the pharmacy (if the trial involves an investigational product), and the regulatory team. When these reviews happen sequentially, the process stalls.

Run reviews in parallel. There is no reason the finance team’s budget review needs to wait for legal to finish the indemnification clause. Route the relevant sections to each stakeholder simultaneously, with each reviewer focused on their area of expertise.

Standardise Positions with a Playbook

Your contract managers should not need to reinvent the wheel for every CTA. A contract playbook that documents your institution’s approved positions on indemnification, IP, publication rights, and subject injury provisions lets the team handle routine negotiations confidently and escalate only the genuinely novel issues.

Separate Budget Negotiation from Legal Terms

Budget and legal negotiations involve different people and different skill sets. Running them on parallel tracks, with a single coordination point, prevents the budget from holding up the legal review and vice versa.

Build a Clause Library

CTAs involve many of the same clauses across different sponsors. Having pre-approved clause variants for indemnification, publication, IP, and subject injury provisions means your team can respond to sponsor redlines with vetted alternative language, rather than drafting from scratch or waiting for counsel review.

Track Active Trials Centrally

Once a CTA is signed, the obligations continue. Protocol amendments need to be reviewed, annual IRB renewals tracked, and close-out milestones managed. A central contract management system provides visibility across all active trials, their amendment status, and upcoming deadlines. This is particularly important when a research coordinator leaves and institutional knowledge needs to survive the transition.

Conclusion

Clinical trial agreements require balancing sponsor timelines against institutional protections, regulatory obligations against operational efficiency, and academic freedom against commercial confidentiality. The institutions that manage this balance well share common traits: they have clear positions documented before the negotiation begins, they run reviews in parallel rather than in sequence, and they treat CTA management as a repeatable process rather than a one-off exercise.

If your institution is managing clinical trial agreements and looking for ways to standardise and accelerate the process, get in touch. We would be happy to show you how Pactly can help.